Author:
Samy Asmaa,Hassan Afnan,Hegazi Nesrine M.,Farid Mai,Elshafei Moustafa
Abstract
AbstractCOVID-19 is a global pandemic that caused a dramatic loss of human life worldwide, leading to accelerated research for antiviral drug discovery. Herbal medicine is one of the most commonly used alternative medicine for the prevention and treatment of many conditions including respiratory system diseases. In this study, a computational pipeline was employed, including network pharmacology, molecular docking simulations, and molecular dynamics simulations, to analyze the common phytochemicals of ginger rhizomes and identify candidate constituents as viral inhibitors. Furthermore, experimental assays were performed to analyze the volatile and non-volatile compounds of ginger and to assess the antiviral activity of ginger oil and hydroalcoholic extract. Network pharmacology analysis showed that ginger compounds target human genes that are involved in related cellular processes to the viral infection. Docking analysis highlighted five pungent compounds and zingiberenol as potential inhibitors for the main protease (Mpro), spike receptor-binding domain (RBD), and human angiotensin-converting enzyme 2 (ACE2). Then, (6)-gingerdiacetate was selected for molecular dynamics (MD) simulations as it exhibited the best binding interactions and free energies over the three target proteins. Trajectories analysis of the three complexes showed that RBD and ACE2 complexes with the ligand preserved similar patterns of root mean square deviation (RMSD) and radius of gyration (Rg) values to their respective native structures. Finally, experimental validation of the ginger hydroalcoholic extract confirmed the existence of (6)-gingerdiacetate and revealed the strong antiviral activity of the hydroalcoholic extract with IC$$_{50}$$
50
of 2.727 $$\upmu \hbox {g}/\hbox {ml}$$
μ
g
/
ml
. Our study provides insights into the potential antiviral activity of (6)-gingerdiacetate that may enhance the host immune response and block RBD binding to ACE2, thereby, inhibiting SARS-CoV-2 infection.
Funder
Zewail City of Science & Technology
Publisher
Springer Science and Business Media LLC
Reference95 articles.
1. Ma, J. Coronavirus: China’s first confirmed Covid-19 case traced back to November 17. In South China Morning Post. https://www.scmp.com/news/china/society/article/3074991/coronavirus-chinas-first-confirmed-covid-19-case-traced-back (2020).
2. Cucinotta, D. & Vanelli, M. Who declares covid-19 a pandemic. Acta Bio Med. Atenei Parmensis 91(1), 157 (2020).
3. W.H. Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (2022)
4. Alamri, M.A., Tahir Ul Qamar, M., Mirza, M.U., Bhadane, R., Alqahtani, S.M., Muneer, I., Froeyen, M., & Salo-Ahen, O.M. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-COV-2 main protease 3clpro. J. Biomol. Struct. Dyn. 1–13 (2020)
5. Cui, J., Li, F. & Shi, Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17(3), 181–192 (2019).